The rise and fall of hydroxychloroquine for the treatment and prevention of COVID-19

Simple item page
dc.contributor.authorLee, Zelynen_ZA
dc.contributor.authorRayner, Craig R.en_ZA
dc.contributor.authorForrest, Jamie I.en_ZA
dc.contributor.authorNachega, Jean B.en_ZA
dc.contributor.authorSenchaudhuri, Eshaen_ZA
dc.contributor.authorMills, Edward J.en_ZA
dc.date.accessioned2021-02-04T07:05:36Z
dc.date.available2021-02-04T07:05:36Z
dc.date.issued2021
dc.descriptionCITATION: Lee, Z. et al. 2021. The rise and fall of hydroxychloroquine for the treatment and prevention of COVID-19. American Journal of Tropical Medicine and Hygiene, 104(1):35–38, doi:10.4269/ajtmh.20-1320.
dc.descriptionThe original publication is available at https://www.ajtmh.org
dc.description.abstractENGLISH ABSTRACT: The efficacy and safety of hydroxychloroquine (HCQ) for the prevention and treatment of COVID-19 has received great attention, and most notably, the enthusiasm for HCQ has been one of politicization rather than science. Laboratory studies and case series published early in the pandemic supported its efficacy. The scientific community raced to conduct observational and randomized evaluations of the drug in all stages of the disease, including prophylaxis, early treatment, and advanced disease. Yet a divisive media response affected recruitment, funding, and subsequent enthusiasm for continuing scientific investigations. Of the more than 300 HCQ trials registered, fewer than 50% report having recruited any patients, and most trials might fail to achieve any useful portions of their intended sample size. Multiple observational studies and two large randomized trials have demonstrated HCQ does not offer efficacy against COVID-19 in hospitalized patients. Prophylaxis studies and early treatment studies provided heterogeneous results and are plagued by low event rates and poor study outcome monitoring. Emerging high-quality evaluations of prophylaxis and early treatment do not support a role for HCQ in these populations. The story of HCQ for COVID-19 has followed a pattern of initial enthusiasm supported by poor quality evidence, followed by disappointment based on more rigorous evaluations. The experience of HCQ in the COVID-19 era calls for the depoliticization of science away from media glare.en_ZA
dc.description.urihttps://www.ajtmh.org/view/journals/tpmd/104/1/article-p35.xml
dc.description.versionPublisher's version
dc.format.extent4 pagesen_ZA
dc.identifier.citationLee, Z. et al. 2021. The rise and fall of hydroxychloroquine for the treatment and prevention of COVID-19. American Journal of Tropical Medicine and Hygiene, 104(1):35–38, doi:10.4269/ajtmh.20-1320.
dc.identifier.issn1476-1645 (online)
dc.identifier.otherdoi:10.4269/ajtmh.20-1320
dc.identifier.urihttp://hdl.handle.net/10019.1/109508
dc.language.isoen_ZAen_ZA
dc.publisherAmerican Society of Tropical Medicine and Hygieneen_ZA
dc.rights.holderAmerican Society of Tropical Medicine and Hygieneen_ZA
dc.subjectCOVID-19 (Disease)en_ZA
dc.subjectDrug efficacyen_ZA
dc.subjectHydroxychloroquineen_ZA
dc.subjectCoronavirus disease-19 -- Treatmenten_ZA
dc.titleThe rise and fall of hydroxychloroquine for the treatment and prevention of COVID-19en_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
lee_rise_2021.pdf
Size:
141.61 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (General Medicine)